Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Fred Hutchinson Cancer Center
With
PRIMARY OBJECTIVES: I. To determine whether systemic administration of interferon (IFN) gamma (recombinant interferon gamma) will increase class I major histocompatibility complex (MHC) expression in synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) tumors. SECONDARY OBJECTIVES: I. To determine whether systemic administration of IFN gamma will increase class II MHC expression in SS and MRCL tumors. II. To examine changes in the immune response to MRCL and SS by examining changes in the immune infiltrates, antibody response and antigen specific T cell response before and after IFN gamma treatment. OUTLINE: Patients receive recombinant interferon gamma subcutaneously (SC) every 7 days for 4 weeks before surgery. After completion of study, patients are followed up at 2 weeks post-surgery.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted